CYP4F2 genetic variant alters required warfarin dose.

摘要: Warfarin is an effective, commonly prescribed anticoagulant used to treat and prevent thrombotic events. Because of historically high rates drug-associated adverse events, warfarin remains underprescribed. Further, interindividual variability in therapeutic dose mandates frequent monitoring until target anticoagulation achieved. Genetic polymorphisms involved metabolism sensitivity have been implicated dose. Here, we describe a novel variant that influences requirements. To identify additional genetic variants contribute requirements, screening DNA genes code for drug-metabolizing enzymes drug transport proteins was undertaken using the Affymetrix transporters panel. A (rs2108622; V433M) cytochrome P450 4F2 (CYP4F2) associated with 3 independent white cohorts patients stabilized on representing diverse geographic regions United States accounted difference approximately 1 mg/day between CC TT subjects. variation CYP4F2 clinically relevant effect requirement.